El Camino Hospital has appointed Paul Billings as acting director and chief science officer of its new Genomic Medicine Institute. Billings is co-founder of GeneSage; co-founder and first medical director of CBR Systems; and advisor for CELLective Dx Corporation. He was previously VP of corporate development and senior geneticist at the Laboratory Corporation of America and an adjunct professor in the department of anthropology at University of California, Berkeley.
DxS appointed Chief Operating Officer Jeff Devlin to its executive board. Before joining DxS this January, Devlin was executive VP of Shire Pharmaceuticals and a partner at Ernst & Young's life sciences division.
Additionally, Peter Collins has been appointed senior VP of business development at DxS. Previously, Collins has held senior executive roles at Vysis, a subsidiary of Abbott Molecular Diagnostics; Quantase, a subsidiary of Bio-Rad Laboratories; as well as Gentronix, Biogenex, and Pronostics.